Last reviewed · How we verify

NCT05230446: PRESENT

PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions

Recruiting now NA Last updated 9 February 2022
What this trial tests

NA trial testing PCI with OCT guidance in Multi Vessel Coronary Artery Disease in 609 participants. Currently enrolling.

Timeline
18 November 2021
Primary endpoint
18 November 2023
18 November 2027

Quick facts

Lead sponsorErasmus Medical Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment609
Start date18 November 2021
Primary completion18 November 2023
Estimated completion18 November 2027
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Erasmus Medical Center

Who can join

Adults 18 to 85, any sex, with Multi Vessel Coronary Artery Disease or Non-ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multi Vessel Coronary Artery Disease

Currently open trials in the same condition.

Other Erasmus Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing